Ilant Health Secured Funding for Outcomes-Based Weight Care
A new model links financial success to patient health results as employer demand for GLP-1 obesity treatments climbs.
Updated on Oct. 5, 2026 in Weight Loss
Live Poll
Do you believe obesity treatment should prioritize lifestyle integration over reliance on weight loss medications?
Ilant Health has raised $22 million in total funding to scale a care model that connects revenue directly to patient health outcomes. The company aims to address metabolic health by integrating nutritional and behavioral support with GLP-1 medications.
Why it matters
Employers are seeking ways to manage rising pharmaceutical costs while preventing long-term chronic disease as GLP-1 drugs represented 10.5% of employer annual claims in 2025. By tying revenue to health success, the model attempts to curb high rates of treatment discontinuation.
Industry claims data shows GLP-1 medications grew to 10.5% of employer claims in 2025, up from 6.9% in 2023. Approximately one-third of patients stop taking these medications within the first month, a trend this new integrated care approach aims to mitigate.
The players
Ilant Health
A healthcare company that provides integrated metabolic care and GLP-1 medication management to patients.
Eli Lilly
A global pharmaceutical company that develops GLP-1 therapies used in metabolic and obesity treatment.
Novo Nordisk
A pharmaceutical manufacturer specializing in diabetes and obesity care therapies.
Kasey Goodpaster
The director of behavioral health at Ilant Health who oversees mental health integration in patient care.
Christina Link
The director of nutrition at Ilant Health who manages dietary and lifestyle programming for members.
The details
Ilant Health uses medical claims data and an algorithm to match individuals with appropriate metabolic treatment options. The platform integrates nutrition and behavioral health, with dedicated directors overseeing these programs. By sharing financial risk with employers, the company receives payment only when specific patient health outcomes are met, moving away from a traditional fee-for-service model.
Timeline
GLP-1 drugs accounted for 6.9% of employer claims in 2023.
GLP-1 drugs accounted for 10.5% of employer claims in 2025.
The CMS BALANCE Model began in Medicaid in May 2026.
Cornucopian Capital led a $15 million Series A funding round in June 2026.
Medicare beneficiaries gained access to obesity GLP-1 drugs for $50 per month in July 2026.
Health Landscape
The push for outcomes-based weight management follows the industry-wide shift toward value-based care exemplified by the Centers for Medicare & Medicaid Services BALANCE Model. These programs aim to move beyond simple drug access toward comprehensive metabolic health improvement.
If you are considering GLP-1 medications for weight management, it is worth discussing with your doctor how your plan integrates behavioral and nutritional support. Tracking your progress through your provider is essential, as the high rate of treatment discontinuation underscores the need for ongoing care.
The takeaway
Integrated care models prioritize long-term metabolic health over simple medication access. Patients should focus on building sustainable habits like nutritional and behavioral support rather than relying solely on pharmacological interventions.
What happens next
The Medicare obesity drug bridge program is currently scheduled to operate through 2027.
Further reading
For more information on managing metabolic health, visit the Weight Loss section.
Source note: This article includes information reported by Forbes.
Live Poll
Do you believe obesity treatment should prioritize lifestyle integration over reliance on weight loss medications?
